Nanorobotics is a preclinical-stage startup on a mission to eradicate cancer by harnessing the power of its breakthrough, patented light-activated nanomolecular platform technology.Nanorobotics platforms leverage the unique characteristics of a Molecular Nanomachines (MNMs), which can drill mechanically through the cell membrane, to develop a pipeline of safe and effective molecular therapies for treating cancers that have shown resistance to conventional therapies.

Nanorobotics leading molecule, MNM96, exhibits an excellent preclinical efficacy and safety profile and is well positioned to advance toward the first human clinical trials in 2025.